AstraZeneca is a British multinational biopharmaceutical company.
• Revenue: $26.1 B
• Market Value: $87.7 B
It is headquartered in London, UK. It is the seventh largest pharmaceutical company in the world in terms of drug sales. AstraZeneca was formed on April 6, 1999 as a result of a successful merger of Astra AB of Sweden and UK-based Zeneca Group PLC. Both the companies shared a similar science-based culture. It is present in more than 100 countries across 5 continents with around 57,500 employees worldwide.
AstraZeneca has a widespread coverage in key therapy areas such as respiratory, inflammation and autoimmunity, and cardiovascular and metabolic disease. It is the market leader in oncology and anaesthesia. It invests substantially in research and development to drive innovation-led growth. Strategic partnering and business development are the key drivers of AstraZeneca’s strategy. In pursuit of a major corporate restructuring, it acquired biotech oncology company Spirogen in 2013 for $440 million. It also rejected a final offer of $55 per share from Pfizer in 2014 which would have valued it at $117 billion.